Results 61 to 70 of about 41,944 (264)

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors

OncoImmunology, 2022
PARP inhibitors are synthetically lethal with BRCA1/2 mutations, and in this setting, accumulation of DNA damage leads to cell death. Because increased DNA damage and subsequent immune activation can prime an anti-tumor immune response, we studied the ...
Anna D. Staniszewska, Joshua Armenia, Matthew King, Chrysiis Michaloglou, Avinash Reddy, Maneesh Singh, Maryann San Martin, Laura Prickett, Zena Wilson, Theresa Proia, Deanna Russell, Morgan Thomas, Oona Delpuech, Mark J. O’Connor, Elisabetta Leo, Helen Angell, Viia Valge-Archer   +16 more
doaj   +1 more source

PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines [PDF]

, 2018
PARP inhibitors (PARPi) are used in a wide range of human solid tumours but a limited evidence is reported in rhabdomyosarcoma (RMS), the most frequent childhood soft-tissue sarcoma.
Camero, S, Camicia, L, Ceccarelli, S, De Felice, F, Dominici, C, Mannarino, O, Marampon,, Marchese, C, Megiorni, F, Mollace, Mg, Pizer, B, Pizzuti, Antonio, Pontecorvi, P, Schiavetti, A, Shukla, R, Tombolini, V, Vescarelli, E   +16 more
core   +1 more source

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.

Annals of Oncology, 2023
BACKGROUND Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is standard of care for some patients with advanced ovarian cancer. We evaluated the efficacy and safety of PARP inhibitor rechallenge.
E. Pujade-Lauraine, F. Selle, G. Scambia, B. Asselain, F. Marmé, K. Lindemann, N. Colombo, R. Mądry, R. Glasspool, I. Vergote, J. Korach, S. Lheureux, C. Dubot, A. Oaknin, C. Zamagni, F. Heitz, L. Gladieff, M. Rubio-Pérez, P. Scollo, C. Blakeley, B. Shaw, I. Ray-Coquard, A. Redondo   +22 more
semanticscholar   +1 more source

Network divergence analysis identifies adaptive gene modules and two orthogonal vulnerability axes in pancreatic cancer

Molecular Oncology, EarlyView.
Tumors contain diverse cellular states whose behavior is shaped by context‐dependent gene coordination. By comparing gene–gene relationships across biological contexts, we identify adaptive transcriptional modules that reorganize into distinct vulnerability axes.
Brian Nelson, Lyanne Delgado‐Coka, Natalia Marchenko, Luisa F. Escobar‐Hoyos, Kenneth R. Shroyer, Alisa Yurovsky, Trey Ideker, Gábor Balázsi, Thomas MacCarthy, Scott Powers   +9 more
wiley   +1 more source

Medical treatment of early stage and rare histological variants of epithelial ovarian cancer [PDF]

, 2015
Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours ...
Biglia, Nicoletta, CODACCI PISANELLI, Giovanni, Colombo, Nicoletta, Cont, Nicoletta Tomasi, D'Alonzo, Marta, Ferrero, Annamaria, Peccatori, Fedro Alessandro   +6 more
core   +3 more sources

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet Oncology, 2021
BACKGROUND There is a high unmet need for treatment regimens that increase the chance of long-term remission and possibly cure for women with newly diagnosed advanced ovarian cancer.
Susana Banerjee, K. Moore, N. Colombo, G. Scambia, Byoung-Gie Kim, A. Oaknin, M. Friedlander, A. Lisyanskaya, A. Floquet, A. Leary, G. Sonke, C. Gourley, A. Oza, A. González-Martín, C. Aghajanian, W. Bradley, E. Holmes, E. Lowe, P. DiSilvestro   +18 more
semanticscholar   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature

BMC Pulmonary Medicine, 2023
Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has demonstrated effectiveness in treating ovarian, breast, and other cancers, particularly those with specific molecular subtypes including, but not limited to, BRCA1/2 mutations ...
Hiroshi Ishimoto, Noriho Sakamoto, Takashi Kido, Mutsumi Ozasa, Shin Tsutsui, Mayako Mori, Daichi Setoguchi, Shinnosuke Takemoto, Yasushi Obase, Yuji Ishimatsu, Chiharu Tomonaga, Kanako Matsumoto, Sachiko Morisaki, Kiyonori Miura, Hiroshi Mukae   +14 more
doaj   +1 more source

Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance

Frontiers in Oncology, 2022
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) are currently being used for treating breast cancer patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic diseases.
Mohammed Hafiz Uddin, Jun-Ying Zhou, Julio Pimentel, Steve M. Patrick, Steve M. Patrick, Steve M. Patrick, Seongho Kim, Seongho Kim, Malathy P. Shekhar, Malathy P. Shekhar, Malathy P. Shekhar, Gen Sheng Wu, Gen Sheng Wu, Gen Sheng Wu   +13 more
doaj   +1 more source

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.

Cancer Cell, 2021
The combination of PD-L1 inhibitor durvalumab and PARP inhibitor olaparib added to standard paclitaxel neoadjuvant chemotherapy (durvalumab/olaparib/paclitaxel [DOP]) was investigated in the phase II I-SPY2 trial of stage II/III HER2-negative breast ...
L. Pusztai, C. Yau, D. Wolf, H. Han, L. Du, A. Wallace, Erica String-Reasor, J. Boughey, A. Chien, A. Elias, H. Beckwith, R. Nanda, K. Albain, A. Clark, K. Kemmer, K. Kalinsky, C. Isaacs, Alexandra Thomas, R. Shatsky, T. Helsten, A. Forero-Torres, Minetta C. Liu, L. Brown-Swigart, E. Petricoin, J. Wulfkuhle, S. Asare, Amy Wilson, R. Singhrao, L. Sit, G. Hirst, S. Berry, A. Sanil, A. Asare, J. Matthews, J. Perlmutter, M. Melisko, H. Rugo, R. Schwab, W. Symmans, D. Yee, L. V. van’t Veer, N. Hylton, A. DeMichele, D. Berry, L. Esserman   +44 more
semanticscholar   +1 more source